Patrick Soon-Shiong, Chairman of Chan Soon-Shiong Family Foundation, Executive Chairman at ImmunityBio, and Executive Chairman of the Los Angeles Times, shared on X:
“So this randomized study says it all. If patients fail chemo and Keytruda then adding more Keytruda or more chemo does not extend survival… 5 months is what this randomized trials show.
Patients with lung cancer who failed all standards of care deserve a chance to live longer with a high quality of life. Science matters.
This data tells it all.
Saudi FDA understood the data and the importance of this finding.”
Title: Continuation of Pembrolizumab with Additional Chemotherapy after Progression with PD-1/PD-L1 Inhibitor Monotherapy in Patients with Advanced NSCLC: A Randomized, Placebo-Controlled Phase II Study
Authors: Hyun Ae Jung, Sehhoon Park, Yoon-La Choi, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn
Read the Full Article on Clinical Cancer Research
Other posts featuring Patrick Soon-Shiong on OncoDaily.